Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01204476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01204476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
Not reported
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrin-producing neuroendocrine tumor, lung carcinoid tumor, metastatic digestive system neuroendocrine tumor g1, pancreatic glucagonoma, pancreatic insulinoma, pancreatic polypeptide tumor, paraganglioma, recurrent digestive system neuroendocrine tumor g1, recurrent merkel cell carcinoma, recurrent pancreatic neuroendocrine carcinoma, regional digestive system neuroendocrine tumor g1, somatostatin-producing neuroendocrine tumor, stage iii merkel cell carcinoma, stage iv merkel cell carcinoma, thyroid gland medullary carcinoma